Anajiva Biopharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 62.15%
- Profit Growth -1791.24%
- Ebitda -12821.21%
- Net Worth -488.44%
- Total Assets 6.42%
About Anajiva Biopharma
Anajiva Biopharma Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 April 2019 (Five years and nine months 23 days old ). Its registered office is in Vishakhapatnam, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chintalapudi Rao, Sanjeeva Chintalapudi, Gayatri Yellapu, and One other member serve as directors at the Company.
Company Details
-
Location
Vishakhapatnam, Andhra Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100AP2019PTC111683
-
Company No.
111683
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Apr 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Anajiva Biopharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chintalapudi Rao
|
Director | 22-Feb-2021 | Current |
|
Sanjeeva Chintalapudi
|
Director | 11-Apr-2019 | Current |
|
Gayatri Yellapu
|
Director | 22-Feb-2021 | Current |
|
Satish Kodavali
|
Director | 11-Apr-2019 | Current |
Financial Performance of Anajiva Biopharma.
Anajiva Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 62.15% increase. The company also saw a substantial fall in profitability, with a 1791.24% decrease in profit. The company's net worth observed a substantial decline by a decrease of 488.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anajiva Biopharma?
In 2023, Anajiva Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Eprosoft India Private LimitedSanjeeva Chintalapudi and Satish Kodavali are mutual person
-
-
Kontinental Operations Llp
Satish Kodavali is a mutual person
-
Genelixir Private Limited
Satish Kodavali is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Anajiva Biopharma?
Anajiva Biopharma has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anajiva Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anajiva Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.